Callan Family Office’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Callan Family Office's VRTX Position: Q2 2026 in Review
Callan Family Office increased its Vertex Pharmaceuticals (VRTX) stake by 3.5% in Q2 2026, buying an estimated $234K and bringing the position to 15,789 shares worth $7.84M. The position accounts for 0.15% of the portfolio, ranked #134.
Callan Family Office first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Callan Family Office held 15,789 shares of Vertex Pharmaceuticals worth $7.84M as of Q2 2026.
- Callan Family Office bought 527 Vertex Pharmaceuticals shares in Q2 2026, an estimated $234K.
- Vertex Pharmaceuticals made up 0.15% of Callan Family Office's portfolio in Q2 2026, its #134 holding.
- Callan Family Office first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
- 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.